Home › Calculator › LIANY Dividend Calculator 2026
LIANY Dividend DRIP Calculator 2026
1102.56% YieldHealthcareLianBio · OTC
Price: $0.04 · Annual div: $0.43/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Calculator settings
Portfolio growth: DRIP vs No DRIP
Annual dividend income growth
💡 What-if scenarios
Click to apply scenario to the calculator
🎯 When LIANY pays your bills
Year your monthly dividend income covers each expense (based on current settings)
Share your LIANY snowball 📈
$10,000 in LIANY → $632531789.37M in 10 years · $48,327,766,423,165.88/month
About LianBio (LIANY) — Dividend Analysis 2026
LianBio is a biopharmaceutical firm dedicated to advancing and marketing therapeutic agents across various critical health sectors, including cardiovascular disorders, oncology, ophthalmological conditions, and inflammatory ailments. Its operations are primarily concentrated in China and the broader Asian region. The company's pipeline features several promising drug candidates targeting a range of severe illnesses. These include mavacamten, aimed at both obstructive and non-obstructive hypertrophic cardiomyopathy, as well as heart failure with preserved ejection fraction. TP-03 is being developed for Demodex blepharitis and meibomian gland dysfunction. For cancer, LianBio is advancing NBTXR3 for head and neck squamous cell carcinoma and other solid tumors, alongside Infigratinib for cholangiocarcinoma (both first-line and second-line settings) and gastric cancers, and BBP-398 also for solid tumors. Furthermore, Omilancor and NX-13 are in development for inflammatory bowel diseases like ulcerative colitis and Crohn's disease. Other programs include LYR-210 for chronic rhinosinusitis and Sisunatovir to combat respiratory syncytial virus. LianBio has established key collaborations, partnering with Tarsus Pharmaceuticals, Inc. on the development and market introduction of TP-03 specifically for Demodex blepharitis. Additionally, it maintains a strategic alliance with Nanobiotix S.A. for NBTXR3, a novel radioenhancer intended for direct intratumoral injection before conventional radiation therapy. Established in 2019, the company's corporate headquarters are located in Princeton, New Jersey.
Compare LIANY with similar stocks
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
Get Your Full LIANY DRIP Report by Email
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open LIANY position with:
🌍 LIANY Yield by Country & Account Type
Real after-tax yield depends on where you live and how you hold LIANY.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 1102.56% | 1099.76% | $110,256 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 937.18% | 934.38% | $93,718 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 882.05% | 879.25% | $88,205 / yr |
| 🇬🇧 UK ISA | 0% | 1102.56% | 1099.76% | $110,256 / yr |
| 🇬🇧 UK Taxable | 8.75% | 1006.09% | 1003.29% | $100,609 / yr |
| 🇨🇦 TFSA | 0% | 1102.56% | 1099.76% | $110,256 / yr |
| 🇨🇦 CA Taxable | 25% | 826.92% | 824.12% | $82,692 / yr |
| 🇦🇺 Super (pension) | 15% | 937.18% | 934.38% | $93,718 / yr |
| 🇦🇺 AU Taxable | 30% | 771.79% | 768.99% | $77,179 / yr |
| 🇩🇪 DE Taxable | 26.375% | 811.76% | 808.96% | $81,176 / yr |
| 🇫🇷 FR Taxable | 30% | 771.79% | 768.99% | $77,179 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
🎯 LIANY Income Goal & Break-Even
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $0.43/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
📅 LIANY Dividend Payment Schedule
LIANY pays quarterly — 4 times per year. Next ex-div: TBD.
📊 LIANY vs Healthcare Benchmarks
How LIANY compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for LIANY sourced from FMP /financial-growth endpoint — real data, not estimates.
🏛️ LIANY Insider Activity
No recent SEC filings reported in the last 90 days.Financial Health Scores
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the LIANY dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
LianBio (LIANY) is currently trading at $0.04, trading near its 52-week low. The current dividend yield is 1102.56% based on an annual payout of $0.43 per share.
LIANY (LianBio) — 1102.56% Dividend Yield Analysis
LianBio (LIANY) is a healthcare stock currently trading at $0.04 with a dividend yield of 1102.56%. The company pays an annual dividend of $0.43 per share. The payout ratio of 50% suggests the dividend is well-covered by earnings.
- Above-average yield (1102.56%) may signal elevated risk — verify sustainability.
Auto-generated from live market data. For educational purposes only — not financial advice.